Cardiometabolic
Boehringer Ingelheim is adding a third target to obesity treatment.
Boehringer Ingelheim has started Phase II testing of BI 3034701, an injectable medicine targeting GLP-1, GIP and NPY2 receptors. The additional pathway is intended to act more directly on hunger, but the company has not yet published detailed efficacy data. The trial will test whether a more complex molecule delivers meaningfully better, safer or more…
Obesity Care Starts Moving Beyond BMI
Canada’s Generic Semaglutide Approval Tests GLP-1 Affordability
India’s Obesity Campaign Dispute Tests the Line Between Awareness and Promotion
England’s Tirzepatide Rollout Shows Approval Is Not Access
Medicare’s GLP-1 Bridge Turns Obesity Coverage Into a Public-Payer Experiment
WHO Makes Obesity Treatment a Global Access Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.